Severe pulmonary hypertension in lung disease: phenotypes and response to treatment

被引:51
作者
Brewis, Melanie J. [1 ]
Church, Alistair C. [1 ]
Johnson, Martin K. [1 ]
Peacock, Andrew J. [1 ]
机构
[1] Golden Jubilee Natl Hosp, Scottish Pulm Vasc Unit, Glasgow G81 4DY, Lanark, Scotland
关键词
TERM OXYGEN-THERAPY; ARTERIAL-HYPERTENSION; NATRIURETIC PEPTIDE; NT-PROBNP; ACUTE EXACERBATIONS; EMPHYSEMA SYNDROME; COPD PATIENTS; GAS-EXCHANGE; DYSFUNCTION; FIBROSIS;
D O I
10.1183/13993003.02307-2014
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Pulmonary hypertension (PH) due to lung disease (World Health Organization (WHO) group 3) is common, but severe PH, arbitrarily defined as mean pulmonary artery pressure >= 35 mmHg is reported in only a small proportion. Whether these should be treated as patients in WHO group 1 (i.e. pulmonary arterial hypertension) with PH-targeted therapies is unknown. We compared the phenotypic characteristics and outcomes of 118 incident patients with severe PH and lung disease with 74 idiopathic pulmonary arterial hypertension (IPAH) patients, all treated with pulmonary vasodilators. Lung disease patients were older, more hypoxaemic, and had lower gas transfer, worse New York Heart Association functional class and lower 6-min walking distance (6MWD) than IPAH patients. Poorer survival in those with lung disease was driven by the interstitial lung disease (ILD) cohort. In contrast to IPAH, where significant improvements in 6MWD and N-terminal pro-brain natruiretic peptide (NT-proBNP) occurred, PH therapy in severe PH lung disease did not lead to improvement in 6MWD or functional class, but neither was deterioration seen. NT-proBNP decreased from 2200 to 1596 pg.mL(-1) (p=0.015). Response varied by lung disease phenotype, with poorer outcomes in patients with ILD and emphysema with preserved forced expiratory volume in 1 s. Further study is required to investigate whether vasodilator therapy may delay disease progression in severe PH with lung disease.
引用
收藏
页码:1378 / 1389
页数:12
相关论文
共 50 条
  • [21] Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery
    Opitz, Isabelle
    Ulrich, Silvia
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S2763 - S2774
  • [22] Iron Deficiency Is Associated With More Severe Pulmonary Vascular Disease in Pulmonary Hypertension Caused by Chronic Lung Disease
    Tatah, Jasmine
    Keen, Jennifer L.
    Prisco, Sasha Z.
    Pritzker, Marc
    Thenappan, Thenappan
    Prins, Kurt W.
    CHEST, 2022, 161 (01) : 232 - 236
  • [23] Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease
    Mittoo, Shikha
    Jacob, Thomas
    Craig, Andrea
    Bshouty, Zoheir
    CANADIAN RESPIRATORY JOURNAL, 2010, 17 (06) : 282 - 286
  • [24] Vasoreactivity and inhaled treprostinil response in interstitial lung disease pulmonary hypertension
    Harder, Eileen M.
    Rahaghi, Farbod N.
    Leopold, Jane A.
    Systrom, David M.
    Washko, George R.
    Waxman, Aaron B.
    ERJ OPEN RESEARCH, 2024, 10 (06)
  • [25] Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease
    Faria-Urbina, Mariana
    Oliveira, Rudolf K. F.
    Agarwal, Manyoo
    Waxman, Aaron B.
    LUNG, 2018, 196 (02) : 139 - 146
  • [26] Clinical assessment for pulmonary hypertension in interstitial lung disease
    Chan, Roseanne K.
    Horrigan, Mark
    Goh, Nicole S. L.
    Khor, Yet H.
    INTERNAL MEDICINE JOURNAL, 2023, 53 (08) : 1415 - 1422
  • [27] Management of Pulmonary Hypertension in Patients with Chronic Lung Disease
    Albert Barbera, Joan
    Blanco, Isabel
    CURRENT HYPERTENSION REPORTS, 2015, 17 (08)
  • [28] Pathophysiology of Pulmonary Hypertension in Chronic Parenchymal Lung Disease
    Singh, Inderjit
    Ma, Kevin Cong
    Berlin, David Adam
    AMERICAN JOURNAL OF MEDICINE, 2016, 129 (04) : 366 - 371
  • [29] Pulmonary hypertension in interstitial lung disease and in chronic obstructive pulmonary disease: different entities?
    Piccari, Lucilla
    Aguilar-Colindres, Ricardo
    Rodriguez-Chiaradia, Diego A.
    CURRENT OPINION IN PULMONARY MEDICINE, 2023, 29 (05) : 370 - 379
  • [30] Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments
    Klinger, James R.
    CARDIOLOGY CLINICS, 2016, 34 (03) : 413 - +